Loading data
BIOANasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 9 m USD | 0 USD | — |
| Research and development expense | 73.97 m USD | 59.04 m USD | 33.89 m USD |
| Operating profit | -92.78 m USD | -78.19 m USD | -48.4 m USD |
| Profit before tax | -80.61 m USD | -71.11 m USD | -63.85 m USD |
| Income tax expense | 0 USD | 0 USD | 0 USD |
| Net income (reported basis) | -80.61 m USD | -71.11 m USD | -63.85 m USD |
| Basic earnings per share | -2.24 USD/share | -6.63 USD/share | -38.17 USD/share |
| Diluted earnings per share | -2.24 USD/share | -6.63 USD/share | -38.17 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.